This session will provide an expert overview of Tislelizumab in the treatment of Non-Small Cell Lung Cancer (NSCLC), highlighting key findings from the RATIONALE clinical program and their relevance to real-world practice. The presentation will discuss Tislelizumab’s unique PD-1 binding characteristics, clinical efficacy and safety data across treatment lines, and comparisons with other PD-1 inhibitors. Through evidence-based discussion, participants will gain updated knowledge on optimizing patient selection, integrating biomarker testing, and sequencing immunotherapy to improve survival and quality of life. The program aims to enhance understanding of next-generation PD-1 inhibitors and promote multidisciplinary collaboration for better patient outcomes